Skip to main content
PMC home page
The BMJ logoLink to The BMJ
editorial
. 1996 Jun 15;312(7045):1493–1494. doi: 10.1136/bmj.312.7045.1493

Ecstasy and neurodegeneration.

A R Green, G M Goodwin
PMCID: PMC2351249  PMID: 8646128

Full text

PDF
1493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colado M. I., Green A. R. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol. 1995 Jul 14;280(3):343–346. doi: 10.1016/0014-2999(95)00298-y. [DOI] [PubMed] [Google Scholar]
  2. Colado M. I., Williams J. L., Green A. R. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol. 1995 Aug;115(7):1281–1289. doi: 10.1111/j.1476-5381.1995.tb15037.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci. 1995 Aug;15(8):5476–5485. doi: 10.1523/JNEUROSCI.15-08-05476.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Green A. R., Cross A. J., Goodwin G. M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 1995 Jun;119(3):247–260. doi: 10.1007/BF02246288. [DOI] [PubMed] [Google Scholar]
  5. Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–980. doi: 10.1126/science.6823561. [DOI] [PubMed] [Google Scholar]
  6. McCann U. D., Ridenour A., Shaham Y., Ricaurte G. A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology. 1994 Apr;10(2):129–138. doi: 10.1038/npp.1994.15. [DOI] [PubMed] [Google Scholar]
  7. McGuire P. K., Cope H., Fahy T. A. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy') Br J Psychiatry. 1994 Sep;165(3):391–395. doi: 10.1192/bjp.165.3.391. [DOI] [PubMed] [Google Scholar]
  8. New Targets for Long Acting Drugs Involving Translocation to the Nucleus. Proceedings of the 6th Biochemical Pharmacology Symposium. Oxford, 22-23 July 1993. Dedicated to Professor Peter Alexander PhD, Dsc. 1922-1993. Biochem Pharmacol. 1994 Jan 13;47(1):1–154. [PubMed] [Google Scholar]
  9. Przedborski S., Kostic V., Jackson-Lewis V., Naini A. B., Simonetti S., Fahn S., Carlson E., Epstein C. J., Cadet J. L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci. 1992 May;12(5):1658–1667. doi: 10.1523/JNEUROSCI.12-05-01658.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ricaurte G. A., Forno L. S., Wilson M. A., DeLanney L. E., Irwin I., Molliver M. E., Langston J. W. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988 Jul 1;260(1):51–55. [PubMed] [Google Scholar]
  11. Vingerhoets F. J., Snow B. J., Tetrud J. W., Langston J. W., Schulzer M., Calne D. B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 1994 Nov;36(5):765–770. doi: 10.1002/ana.410360513. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES